Skip to content

KRAKacquisition KRAQ Deferred Offering Costs Noncurrent

Deferred Offering Costs Noncurrent at other companies

Enliven Therapeutics logo
Enliven TherapeuticsELVN
$217K
FCR
FutureCrest Acquisition FCRS
$12.25M
Annexon logo
AnnexonANNX
$445K+449%
Schering-Plough logo
Schering-PloughSGP
$0
Immix Biopharma, Inc. logo
Immix Biopharma, Inc.IMMX
$164.72K
Mineralys Therapeutics, Inc. logo
Mineralys Therapeutics, Inc.MLYS
$200K-33.3%

Other financials

Income statement

See full
Operating income-$11.0M
Net income-$8.9M
EPS (diluted)-$0.01

Balance sheet

See full
Cash & equivalents$824.6K
Total debt$77.4K
Total equity-$19.9M
Total assets$348.0M

Cash flow

See full
Operating cash flow-$669.9K

Valuation

See full
Market cap$430.77M+0.9%
Enterprise value$430.02M

Returns & leverage

See full
Debt / equity-0×
Current ratio7.7×

Where this comes from

Reported directly by KRAKacquisition in its filing.

Tagged under the XBRL concept kraqu:DeferredOfferingCostsNoncurrent.

The official record: KRAKacquisition ’s 10-K, filed March 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about KRAKacquisition 's deferred offering costs noncurrent.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is KRAKacquisition 's deferred offering costs noncurrent?
KRAKacquisition (KRAQ) reported deferred offering costs noncurrent of $436.02K in Q4 2025.
What does deferred offering costs noncurrent mean?
Represents capitalized costs associated with a planned equity offering or business combination that are expected to be realized beyond the next twelve months. These costs are typically deferred until the completion of the transaction, at which point they are reclassified or amortized. This metric reflects the long-term investment in capital-raising activities.